Table Info

Table 4.

Predicted discontinuous and linear epitopes of polytope of envelope protein of SARS CoV2 using http://tools.iedb.org/ellipro/result/predict/

Predicted Discontinuous Epitope(s)
No.	Residues			Number of residues	Score
1	_:V2, _:K3, _:N4, _:L5, _:N6, _:S7, _:S8			11	0.645
2	_:P26, _:F28, _:Y29, _:V30, _:Y31, _:C32, _:S33, _:S34, _:L35, _:V36, _:K37, _:P38, _:S39, _:Y41, _:V42, _:C43, _:S44			5	0.577
Predicted Linear Epitope(s)
No.	Start	End	Peptide	Number of residues	Score
1	1	9	RVKNLNSSR	9	0.755
2	28	38	FYVYCSSLVKP	11	0.645
3	40	44	FYVCS	5	0.577

Declarations

Acknowledgments

The author profusely acknowledges the management of Vignan’s Foundation for Science, Technology and Research (Deemed to be University) for providing the facility through Centre of Excellence and DST FIST Net-working lab (LSI-576/2013).

Author contributions

The author contributed solely to the work. The concept developed and content projected in the present article are original and prepared by the author.

Conflicts of interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Available with the author.

Funding

No funding.

Copyright

References

Alturki SO, Alturki SO, Connors J, Cusimano G, Kutzler MA, Izmirly AM, et al. The 2020 pandemic: current SARS-CoV-2 vaccine development. Front Immunol. 2020;11:1880. [DOI] [PubMed] [PMC]

Charonis SA, Tsilibary EP, Georgopoulos AP. In silico investigation of binding affinities between human leukocyte antigen class I molecules and SARS-CoV-2 virus spike and ORF1ab proteins. Explor Immunol. 2021;1:16–26. [DOI]

Sreerama K. In silico design of multiepitope vaccine candidate against SARS CoV and CoV2. Vaccine Research. 2020;7:61–73.

Joshi A, Joshi BC, Mannan MA, Kaushik V. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach. Inform Med Unlocked. 2020;19:100338. [DOI] [PubMed] [PMC]

Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620. [DOI] [PubMed] [PMC]

hCoV-19 Spike Glycoprotein Mutation Surveillance Dashboard [Internet]. GISAID. c2021 - [cited 2021 Jun 1]. Available from: https://www.gisaid.org/spike

Tilocca B, Soggiu A, Musella V, Britti D, Sanguinetti M, Urbani A, et al. Molecular basis of COVID-19 relationships in different species: a one health perspective. Microbes Infect. 2020;22:218–20. [DOI] [PubMed] [PMC]

Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, et al. Design of a multiepitope-based peptide vaccine against the E protein of human COVID-19: an immunoinformatics approach. BioMed Res Int. 2020;2683286. [DOI]

Tilocca B, Soggiu A, Sanguinetti M, Babini G, De Maio F, Britti D, et al. Immunoinformatic analysis of the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19. Microbes Infect. 2020;22:182–7. [DOI] [PubMed] [PMC]

10.

Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547–9. [DOI] [PubMed] [PMC]

11.

Roychoudhury P, Greninger A, Jerome K. Envelope protein [Severe acute respiratory syndrome coronavirus 2]. GenBank: QIS30437.1 [submitted 2020 Mar 28]. Available from: https://www.ncbi.nlm.nih.gov/protein/QIS30437.1

12.

Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–9. Erratum in: Nature. 2020;580:E7. [DOI] [PubMed] [PMC]

13.

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–90. [DOI] [PubMed] [PMC]

14.

Krupanidhi S, Abraham Peele K, Venkateswarulu TC, Ayyagari VS, Nazneen Bobby M, John Babu D, et al. Screening of phytochemical compounds of Tinospora cordifolia for their inhibitory activity on SARS-CoV-2: an in silico study. J Biomol Struct Dyn. 2020; [Epub ahead of print]. [DOI]

15.

Tilocca B, Soggiu A, Sanguinetti M, Musella V, Britti D, Bonizzi L, et al. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. Microbes Infect. 2020;22:188–94. [DOI] [PubMed] [PMC]

16.

Abraham Peele K, Srihansa T, Krupanidhi S, Ayyagari VS, Venkateswarulu TC. Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study. J Biomol Struct Dyn. 2021;39:3793–801. [DOI] [PubMed] [PMC]

17.

Ayyagari VS, TC V, Srirama K. Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach. J Biomol Struct Dyn. 2020; [Epub ahead of print]. [DOI]

18.

Peele KA, Kumar V, Parate S, Srirama K, Lee KW, Venkateswarulu TC. In silico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2. J Pharm Sci. 2021;110:2346–54. [DOI] [PubMed] [PMC]

19.

Khairkhah N, Aghasadeghi MR, Namvar A, Bolhassani A. Design of novel multiepitope constructs-based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis. PLoS One. 2020;15:e0240577. [DOI]

20.

CNBC. WHO renames COVID-19 variants from India as ‘Delta’ and ‘Kappa’. Available from: https://www.cnbctv18.com/healthcare/who-names-covid-19-variants-from-india-as-delta-kappa-9495731.htm. [Last accessed on Jun 1, 2021].